National Cancer Institute - Cancer.gov
This issue of Milestones highlights some of our scientific advances in FY 2022-2023.
A detailed molecular analysis reveals four subtypes of a common brain cancer.
A second look reveals a highly effective lymphoma treatment.
Breast cancer cells undergo dangerous reprogramming within passageways that connect tumors to the bloodstream.
Artificial intelligence untangles the cellular signals that matter for anticancer immunity.
A potential new marker for immunotherapy response could help guide treatment decisions.
Aggressive breast and prostate cancers in African Americans have distinct molecular features.
To fight cancer, T cells must first overcome a tumor’s hostile environment to reach their target.
Elusive tumor-targeting T cells share a telltale gene activity signature.
The architectural details of a notorious cancer-promoting protein offer clues about how to keep it safely switched off.
A simple approach using viral peptides shows efficacy against diverse tumor types in mice.
New faculty join CCR each year to contribute to our work of making breakthrough scientific discoveries to find cures and treatments for cancer. We also recognize current faculty who have started new roles within CCR.
We are proud of our CCR awardees who represent a spectacular array of accomplishments.
Take a look at our year as told by the numbers to see a snapshot of the breakthrough scientific discoveries and important work happening at CCR.